Premium
HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN‐LABEL, PHASE II STUDY
Author(s) -
Nastoupil L.J.,
Westin J.,
Fowler N.,
Fanale M.,
Samaniego F.,
Oki Y.,
Obi C.,
Cao J.,
Cheng X.,
Ma M.,
Wang Z.,
Chu F.,
Feng L.,
Zhou S.,
Davis R.E.,
Neelapu S.S.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_108
Subject(s) - medicine , pembrolizumab , rituximab , follicular lymphoma , clinical endpoint , phases of clinical research , gastroenterology , adverse effect , oncology , lymphoma , neutropenia , immunology , immunotherapy , cancer , clinical trial , chemotherapy